<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03244332</url>
  </required_header>
  <id_info>
    <org_study_id>2013/06JUI/358</org_study_id>
    <nct_id>NCT03244332</nct_id>
  </id_info>
  <brief_title>HEMOCC Study. Hemostasis in Cirrhotic Children.</brief_title>
  <acronym>HEMOCC</acronym>
  <official_title>HEMOCC Study Hemostasis in Cirrhotic Children : Assessment of Risk Factors of Spontaneous Bleeding From Oesophageal Varices in Cirrhotic Children Waiting for a Graft.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cliniques universitaires Saint-Luc- Université Catholique de Louvain</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective investigations into the role of hemostatic factors in the risk of variceal
      bleeding among children with chronic liver disease (thromboelastometry e.g) is still
      required. A better understanding of these factors would permit better risk stratification and
      targeted prophylaxis or therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigators aim to start a prospective and observational study over a 2 years period.

      First, the investigators will identify all children suffering from cirrhosis irrespective of
      underlying etiology and/or portal hypertension coming into the pediatric
      hepatogastroenterology unit at Saint-Luc University Clinics. Any patient with a congenital or
      acquired thrombophilia/haemorrhagic disorder will be excluded. The investigators expect to
      include 20 to 30 children in the study.

      The investigators will meet the parents to give them explanations about this study and its
      implications. Then the investigators will get the free and informed consent about the
      participation to this clinical study. Parents are obviously free to refuse to take part in
      this clinical study and to retire from it at any moment.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 18, 2013</start_date>
  <completion_date type="Actual">July 15, 2017</completion_date>
  <primary_completion_date type="Actual">July 15, 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The investigators aim to start a prospective and observational study over a 2 years period.
First, the investigators will identify all children suffering from cirrhosis irrespective of underlying etiology and/or portal hypertension coming into the pediatric hepatogastroenterology unit at Saint-Luc University Clinics. Any patient with a congenital or acquired thrombophilia/haemorrhaegic disorder will be excluded.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To evaluate risk factors of spontaneous bleeding from oesophageal varices which are independant of liver functions</measure>
    <time_frame>over 2 year period</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Esophageal and Gastric Varices</condition>
  <condition>Child, Only</condition>
  <arm_group>
    <arm_group_label>Decompensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children suffering from decompensated cirrhosis and needing an orthotopic liver transplantation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Compensated cirrhosis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis (portal vein thrombosis e.g)</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting Clinical Data</intervention_name>
    <description>Clinical data as height, weight, mid upper arm circumference, jaundice, portal hypertension signs (ascites, splenomegaly, umbilical veinous circulation)</description>
    <arm_group_label>Decompensated cirrhosis</arm_group_label>
    <arm_group_label>Compensated cirrhosis</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Collecting laboratory data</intervention_name>
    <description>Laboratory data as CRP, hemogram, albumin, total and conjugated bilirubin, creatinin, urea, liver enzymes, tests of hemostasis.</description>
    <arm_group_label>Decompensated cirrhosis</arm_group_label>
    <arm_group_label>Compensated cirrhosis</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children suffering from decompensated cirrhosis and needing an orthotopic liver
             transplantation

          -  Children suffering from a compensated cirrhosis (compensated cirrhosis with kasai
             surgery in biliary atresia patients e.g) or from portal hypertension without cirrhosis
             (portal vein thrombosis e.g)

          -  Each patient will have a comprehensive assessment of portal hypertension (abdominal
             US-Doppler and upper gastrointestinal endoscopy) and hemostasis

        Exclusion Criteria:

          -  No underlying disease which can alter hemostasis (hemophilia, sepsis…)

          -  No medication which can alter hemostasis (aspirin, anti-inflammatory drugs,…)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>4 Months</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Xavier Stephenne, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Cliniques universitaires Saint-Luc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cliniques Universitaires Saint-Luc</name>
      <address>
        <city>Brussels</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 27, 2017</study_first_submitted>
  <study_first_submitted_qc>August 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2017</study_first_posted>
  <last_update_submitted>August 8, 2017</last_update_submitted>
  <last_update_submitted_qc>August 8, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal and Gastric Varices</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemostatics</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
    <ipd_description>There is no plan at this time</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

